Seawolf Therapeutics discloses earlier seed led by Versant Ventures
The founding investor led the seed financing before the company’s separately announced Series A.
Seawolf Therapeutics named Versant Ventures as the lead investor in its seed round when it emerged from stealth on 16 November 2026. The biotechnology company did not disclose the seed amount or closing date. Its announced $100 million total spans both the seed and the subsequent Series A, whose broader syndicate includes pharmaceutical and biotechnology investors.
Use of funds
Advance DNA-based therapeutics